Accessibility Menu
Hls Therapeutics logo

Hls Therapeutics(OTC) HLTRF

Market Cap$93.20MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2018)-51%
5 Year-78%
1 Year-19%
1 Month-1%
$2.98
-3.25%
-0.10Today
Hls Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 2.982026-07-31
Hls Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-0.67%USD 3.002026-07-23
1 month-0.67%USD 3.002026-06-30
3 month-13.37%USD 3.442026-05-01
Year to date-13.12%USD 3.432025-12-31
1 year-19.46%USD 3.702025-07-31
3 year-35.22%USD 4.602023-07-31
5 year-77.94%USD 13.512021-07-16
Since inception-50.79%USD 6.062018-08-13

Hls Therapeutics Financials at a Glance

Market Cap

$93.20MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$55.80M

Net Income (TTM)

-$10.28M

EPS (TTM)

-$0.33

P/E Ratio

-9.10

Dividend

$0.00

Beta (Volatility)

0.01 (Low)

Price

$2.98

Volume

100

Open

$2.98

Previous Close

$2.98

Daily Range

$2.98 - $2.98

52-Week Range

$2.98 - $4.02

Estimated Earnings Date

Aug 13, 2026

HLTRF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Hls Therapeutics

HLS Therapeutics Inc. is a specialized pharmaceutical company focused on acquiring and commercializing medicinal products, primarily in the central nervous system (CNS) and cardiovascular (CV) therapeutic areas. The company operates in Canada, the United States, and internationally, offering a diverse range of products and services.

Products and Services
  • Clozaril, an atypical antipsychotic for schizophrenia
  • Vascepa, composed of icosapent ethyl capsules
  • PERSERIS, an injectable formulation for schizophrenia treatment
Growth Outlook
  • Recent quarterly revenue reached $12.69 million, showing potential for growth
  • Gross profit margin improved to 36.1% in the latest quarter
  • Expansion into new therapeutic areas may drive future revenue increases
Financial Highlights
  • Trailing twelve months (TTM) revenue of $54.5 million indicates steady performance
  • Operating income margin improved to -17.2% in the latest quarter
  • Cash flow from operations was $6.28 million, reflecting operational efficiency
HLS Therapeutics Inc. has established itself as a key player in the pharmaceutical industry, particularly in the CNS and CV sectors. The company's product offerings, including Clozaril and Vascepa, cater to significant medical needs, positioning it well for future growth. Recent financial performance shows promising trends, with a notable increase in revenue and improvements in gross profit margins. The company’s focus on expanding its therapeutic portfolio may further enhance its market presence and revenue potential. Investors may find HLS Therapeutics an intriguing opportunity within the healthcare sector, given its strategic positioning and recent financial results.
AI Generated • Aug 1, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

85

CEO

Craig Millian, MBA

Website

www.hlstherapeutics.com

Headquarters

Etobicoke, ON M9W 6L2, CA

HLTRF Financials

Key Financial Metrics (TTM)

Gross Margin

61.69%

Operating Margin

-7.34%

Net Income Margin

-18.42%

Return on Equity

-16.54%

Return on Capital

-3.75%

Return on Assets

-7.82%

Earnings Yield

-10.99%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$93.20MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

31.27M

Volume

100

Avg. Volume

187.222

Financials (TTM)

Gross Profit

$34.42M

Operating Income

-$4.10M

EBITDA

$17.80M

Operating Cash Flow

$19.80M

Capital Expenditure

-$1.40M

Free Cash Flow

$18.40M

Cash & ST Invst.

$12.37M

Total Debt

$44.07M

Hls Therapeutics Performance Analysis

Hls Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 61,467,0002.4%
20232023-12-31USD 63,074,0002.6%
20242024-12-31USD 56,619,000-10.2%
20252025-12-31USD 55,500,000-2.0%
Hls Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3012.3%
Q32025-09-30-4.7%
Q42025-12-3114.2%
Q12026-03-31-17.8%
Hls Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.7378.5%
20232023-12-31USD -0.8517.3%
20242024-12-31USD -0.62-27.7%
20252025-12-31USD -0.39-36.1%
Hls Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3037.1%
Q32025-09-30-36.2%
Q42025-12-3163.9%
Q12026-03-31-67.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$12.69M

+0.5%

Gross Profit

$4.58M

-55.2%

Gross Margin

36.12%

N/A

Market Cap

$93.20MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.10M

N/A

Employees

85

N/A

Net Income

-$2.27M

+48.9%

EBITDA

$3.27M

+12.2%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$12.37M

-30.3%

Total Debt

$44.07M

-30.9%

Accounts Receivable

$8.16M

+4.6%

Inventory

$7.39M

-1.3%

Long Term Debt

$39.34M

-32.2%

Short Term Debt

$4.72M

-17.1%

Return on Assets

-7.82%

N/A

Return on Invested Capital

-3.99%

N/A

Free Cash Flow

$6.28M

+78.3%

Operating Cash Flow

$6.28M

+77.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
JUSHFJushi Holdings Inc.
$0.42+1.20%
AAWHAscend Wellness Holdings, Inc.
$0.36-6.49%
ORXOYOrexo AB (publ)
$1.77+0.00%
LOVFFCannara Biotech Inc.
$1.42+7.33%

Trending Stocks

Symbol / CompanyPricePrice Chg
SQQQProShares Trust - ProShares UltraPro Short Qqq
$41.36-0.05%
NVDANvidia
$207.93+0.04%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.89+0.08%
AMZNAmazon
$284.15+0.05%

Questions About HLTRF

What is the current price of Hls Therapeutics?

Hls Therapeutics is trading at $2.98 per share.

What is the 52-week range for Hls Therapeutics?

Over the past 52 weeks, Hls Therapeutics has traded between $2.98 and $4.02.

How much debt does Hls Therapeutics have?

As of the most recent reporting period, Hls Therapeutics reported total debt of $43.93M.

How much cash does Hls Therapeutics have on hand?

Hls Therapeutics reported $12.33M in cash and cash equivalents in its most recent financial results.

What is Hls Therapeutics’s dividend yield?

Hls Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services